GeneDx Reports First Quarter 2024 Financial Results and Business Highlights

Reported first quarter 2024 revenue from continuing operations1 of $61.5M with 96% year-over-year growth of exome and genome test revenue Expanded first quarter 2024 adjusted gross margins2 from continuing operations to 61% Narrowed first quarter 2024 adjusted net loss2 to$ 8.5M and delivered 71% year-over-year cash burn reduction Raised guidance to deliver between $235M and$ 245M in FY 2024 revenue and reiterate path to profitability in 2025 GeneDx to host conference call today at 4:30 p.m. ET STAMFORD, C ...